← Back to Search

Communication Tool Training for Kidney Failure

N/A
Waitlist Available
Led By Jeniann Yi, MD
Research Sponsored by University of Wisconsin, Madison
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Must not have
Currently on dialysis
Do not speak English
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from enrollment for up to 2 years
Awards & highlights
No Placebo-Only Group

Summary

This trial will test whether the "Best Case/Worse Case" communication tool can help patients with end-stage renal disease receive appropriate palliative care and improve communication between patients and their caregivers.

Who is the study for?
This trial is for older adults with severe kidney disease (eGFR ≤ 24) who are not on dialysis but may have had it before or have the access in place. They must be over 80, have other serious illnesses, or their doctor wouldn't be surprised if they passed away within a year. Participants should speak English and be able to make decisions.
What is being tested?
The study tests a 'Best Case/Worst Case' communication tool training for doctors at nephrology clinics. It aims to see if this improves end-of-life care quality and decision-making for patients with end-stage renal disease by comparing trained doctors to those waiting for training.
What are the potential side effects?
Since this trial involves communication training rather than medical treatment, there are no direct physical side effects expected from participating in the study.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I am currently receiving dialysis.
Select...
I do not speak English.
Select...
I am unable to make my own medical decisions.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from enrollment for up to 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and from enrollment for up to 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Receipt of palliative care consult within 12 months of study enrollment, as determined by chart review or report by patient or caregiver
Secondary study objectives
Caregiver-reported general quality of communication (QOC) received from study nephrologist
Caregiver-reported health related quality of life
Caregiver-reported quality of dying and death
+13 more

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Best Case/Worst Case communication toolExperimental Treatment1 Intervention
The participant's enrolled nephrologist will have completed training on the Best Case/Worst Case communication tool and will be encouraged to use it with the participant.
Group II: Usual CareActive Control1 Intervention
Usual care conversations are typically focused on mode and timing of dialysis, management of electrolytes and scheduling of laboratory testing. Conservative management or a treatment option of "no dialysis" is rarely mentioned.

Find a Location

Who is running the clinical trial?

Icahn School of Medicine at Mount SinaiOTHER
903 Previous Clinical Trials
541,360 Total Patients Enrolled
University of Colorado, DenverOTHER
1,800 Previous Clinical Trials
2,821,525 Total Patients Enrolled
West Virginia UniversityOTHER
184 Previous Clinical Trials
64,066 Total Patients Enrolled

Media Library

Best Case/Worst Case communication tool training Clinical Trial Eligibility Overview. Trial Name: NCT04466865 — N/A
Kidney Failure Research Study Groups: Usual Care, Best Case/Worst Case communication tool
Kidney Failure Clinical Trial 2023: Best Case/Worst Case communication tool training Highlights & Side Effects. Trial Name: NCT04466865 — N/A
Best Case/Worst Case communication tool training 2023 Treatment Timeline for Medical Study. Trial Name: NCT04466865 — N/A
~8 spots leftby Jan 2025